Cool,
Question regarding Aurora 2 trial:
Here is what I understand:
- that Aurora 2 is a continuation of Aurora 1 for an additional 24 months (with patients from Aurora 1 rolling over into Aurora 2) with the the purpose being "to assess the long-term safety and tolerability of voclosporin, added to the standard of care treatment in LN, for an additional 24 months".
Here is my question:
Is this a blinded study? (apologize if this is a dumb question). I would assume that it is not ... i.e., that they know who the patients are, and that AUPH will provide updates on the status of this trial each Q.
The reason I ask is that the study will not be completed until 2021 ... that's a long ways out ...
WT